(Total Views: 520)
Posted On: 06/20/2021 11:18:03 PM
Post# of 154143
Ohm20,
I believe you are once more correct. My hope/expectation is that the secondary and exploratory endpoints will help choose the primary endpoint for phase 3 but also discern which subset of patients will best benefit from leronlimab.
Inclusion and exclusion criteria are valuable.
Rockleo, onetime poster here, has noted that leronlimab administration in patients only high-flow oxygen, as opposed to those who decompensated abruptly, is likely to have poor results due to the fibrosis prior to leronlimab administration.
This sort of observation in LH phase 3 will be valuable.
Every drug has an applicable population for administration.
I believe you are once more correct. My hope/expectation is that the secondary and exploratory endpoints will help choose the primary endpoint for phase 3 but also discern which subset of patients will best benefit from leronlimab.
Inclusion and exclusion criteria are valuable.
Rockleo, onetime poster here, has noted that leronlimab administration in patients only high-flow oxygen, as opposed to those who decompensated abruptly, is likely to have poor results due to the fibrosis prior to leronlimab administration.
This sort of observation in LH phase 3 will be valuable.
Every drug has an applicable population for administration.
(6)
(0)
